CancerQuest2020 (CCQ2020) is focused on building an AI-driven model of ovarian cancer that will predict drug response and outcome. Predictive models embody the knowledge from these profiles to create a “computational expert” or a “virtual patient” that can be queried.

MINNEAPOLIS, March 12, 2020 -- Predictive Oncology Inc. (NASDAQ: POAI) (“POAI” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”).

MINNEAPOLIS, April 01, 2020 -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial.

Predictive Oncology (POAI)  has, with the announced acquisition of Soluble Therapeutics and the subsequent partnership and licensing of a novel nanoparticle vaccine technology platform recently developed by Dr. Daniel Carter, entered the race to develop a COVID19 vaccine. The ground-breaking vaccine technology is based on a self-assembling nanoparticle called NSP10 which follows a foundational vaccine platform developed earlier by Dr. Carter and his team, using another self-assembling protein called ferritin (1).

TumorGenesis, Inc. a subsidiary of Predictive Oncology, Inc. (POAI) has selected US Biological Corporation of Salem, Massachusetts as the manufacturer and distributor of its innovative culture media for growing ovarian tumor cells. Unlike traditional cell culture media, which select for one or two fast growing cell types, TumorGenesis media are specially formulated to help researchers isolate and maintain the unique histological and basic biological signatures of heterogeneous ovarian cell types while growing them in the laboratory. Available for purchase via US Biological in Q1-2020, the new media are being launched at a time when, according to MarketWatch, the global cell culture media market is growing at a healthy 8.4% CAGR, driven mainly by the increased use of biological based drugs such as immune therapies, and is expected to reach US $2,360 Million by 2024.

Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that based on a notification letter (the “Notification Letter on Compliance”) recently received from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (the “Nasdaq”), the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the “Minimum Bid Price Requirement”). On November 16, 2018, the Company received a notification letter from the Nasdaq (the “Notification Letter on Deficiency”) indicating that the closing bid price per share had been below $1.00 for a period of 30 Consecutive business days and that the Company did not meet the Minimum Price Bid Requirement.

The outstanding principal amount of the note was increased by $120,000 to a current principal amount of $2,029,104, and the Company issued 15,000 shares of common stock to the investor in connection with certain amended terms. Predictive Oncology (POAI) operates through five segments (Domestic, International, Clinical, CRO and DCHIP), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.

MINNEAPOLIS, Dec. 09, 2019 -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery.

NEW YORK, April 22, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio — Predictive Oncology (POAI) today announces that Company director and CEO Dr. Carl Schwartz, in an interview with NetworkNewsWire (NNW), discussed the Predictive Oncology’s distinctive business model and significant changes management is making to position the Company for the future. The broadcast of the exclusive audio interview produced by NNW, a financial news and content distribution company and one of 40+ brands in the InvestorBrandNetwork (IBN), can be heard at http://nnw.fm/o7Ysq. The interview discusses the evolution of Predictive Oncology.

Ms. Prior, CPA, 57, is the founder and CEO of Priorities Group, Inc., a provider of CFO services to small and mid-sized businesses. Most recently, Ms. Prior was CFO at Schiller Grounds Care, a privately held lawn equipment manufacturing company; CFO at Global Specimen Solutions, a privately held technology and services company for specimen and consent management, subsequently purchased by Covance; CFO at Gentris Corp., a privately held pharmacogenomics company subsequently purchased by Cancer Genetics, Inc.; and CFO at Greatwide Truckload Management, a $300 million subsidiary of a $1 billion private equity owned logistics company. Ms. Prior also served as Controller and Director of Internal Control for Tasty Baking Company, a publicly traded (NYSE) regional baking company, and Controller of PCI Services, a subsidiary of publicly held Cardinal Health.

Previously, he was the Chief Scientific Officer of the Clinical and Translational Genome Research Institute, a Florida 501(c)3 non-profit corporation. During that time, he also held a courtesy faculty appointment in the Department of Biological Sciences at Florida Gulf Coast University.

Pursuant to the offering, the Company sold and issued 1,650,166 shares of common stock (or common stock equivalents) and issued Series A warrants to acquire 1,650,166 shares of Common Stock at $1.88 per share, exercisable immediately and terminating five and one-half years after the date of issuance, and Series B warrants to acquire 1,650,166 shares of Common Stock at $1.88 per share, exercisable immediately and terminating two years after the date of issuance. The Company intends to use the net proceeds for general corporate purposes.

Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it entered into a $15 million common stock purchase and registration rights agreement with Oasis Capital, LLC, a Puerto Rico limited liability company (“Oasis Capital”), to purchase from the Company up to Fifteen Million Dollars ($15,000,000.00) of the Company’s Common Stock. Under the purchase agreement, Predictive Oncology has the right to sell up to $15 million of its stock to Oasis Capital over a 36-month period, upon satisfaction of the conditions in the purchase agreement including the effectiveness of a resale registration statement which has occurred.

Predictive Oncology has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 1,396,826 shares of common stock. The warrants have an exercise price equal to $1.45 per share, are exercisable immediately upon issuance and will expire five and one-half years from the issuance date. The Company currently intends to use up to $487,000 of the net proceeds from the offering to repay certain indebtedness to Oasis Capital, LLC, and the remainder for working capital purposes.

As previously announced, Predictive Oncology has determined that it will focus its resources on its primary mission of applying artificial intelligence to precision medicine and drug discovery. Skyline Medical’s patented, FDA-approved STREAMWAY System is the first truly continuous, direct-to-drain fluid disposal system designed specifically for medical applications.

Artificial intelligence (AI) and machine learning (ML) are very much a part of this race, from predicting virus spread to identifying potential new treatments. CoRE is a predictive model-building platform for drug screening and optimization campaigns that uses hybrid machine learning approaches to rapidly build predictive models to drive wet lab experimentation.

Predictive Oncology (POAI) has, with the announced acquisition of Soluble Therapeutics, Inc. and the subsequent partnership and licensing of a novel nanoparticle vaccine platform recently developed by Dr. Daniel Carter, entered the race to develop a COVID-19 vaccine. The groundbreaking vaccine technology being developed by Dr. Carter is based on a self-assembling nanoparticle called NSP-10 (NSP is Non Specific Protein) which follows a foundational vaccine platform developed earlier by Dr. Carter and his team, using another self-assembling protein called ferritin (1), an iron storage protein found in all living things.

Predictive Oncology (POAI) today announced that it has entered into an Exchange Agreement relating to a $2.1 million promissory note of the Company with Dr. Carl Schwartz, the company’s Chief Executive Officer. Under the agreement, Dr. Schwartz has exchanged the note for newly issued shares of common stock, $0.01 par value of the Company at market value.

MINNEAPOLIS, Jan. 24, 2020 -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial.

The closing of the private placement is subject to the satisfaction of certain customary closing conditions set forth in the securities purchase agreement. The Company intends to use the net proceeds for general corporate purposes.